{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"29"},{"groupId":"OG003","value":"28"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"35"},{"groupId":"OG002","value":"40"},{"groupId":"OG003","value":"41"}],"units":"Participants"}],"description":"Laboratory test abnormality parameters included: hematology- hemoglobin (gram per deciliter \\[g/dL\\]), hematocrit (%), erythrocytes (10\\^12/Liter \\[L\\]) less than (\\<) 0.8\\*lower limit of normal (LLN); platelets (10\\^9/L) \\<0.5\\*LLN to more than (\\>) 1.75\\*upper limit of normal (ULN); leukocytes (10\\^9/L) \\<0.6\\*LLN to \\>1.5\\*ULN; lymphocytes, neutrophils (10\\^9/L) \\<0.8\\*LLN to \\>1.2\\*ULN. Clinical chemistry- bilirubin, glucose (mg/dL) \\>1.5\\*ULN; aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase (Units/L \\[U/L\\]) \\>3.0\\*ULN; protein, albumin (gram \\[g\\]/dL) \\<0.8\\*LLN; urea (mmol/L) \\>1.3xULN; creatinine (mg/dL) \\>1.3\\*ULN; sodium (milliequivalents \\[mEq\\]/L) \\<0.95\\*LLN; potassium (mEq/L) \\<0.9\\*LLN to \\>1.1\\*ULN.","groups":[{"description":"Part A: Participants were randomized to receive placebo matching to Ponsegromab SC Q4W up to 12 weeks (total of 3 doses).","id":"OG000","title":"Part A: Placebo"},{"description":"Part A: Participants were randomized to receive Ponsegromab 100 mg SC Q4W up to 12 weeks (total of 3 doses).","id":"OG001","title":"Part A: Ponsegromab 100 mg"},{"description":"Part A: Participants were randomized to receive Ponsegromab 200 mg SC Q4W up to 12 weeks (total of 3 doses).","id":"OG002","title":"Part A: Ponsegromab 200 mg"},{"description":"Part A: Participants were randomized to receive Ponsegromab 400 mg SC Q4W up to 12 weeks (total of 3 doses).","id":"OG003","title":"Part A: Ponsegromab 400 mg"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety analysis set included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention. Participants were analyzed according to the study intervention they actually received. Here, ''Overall Number of Participants Analyzed'' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Day 1 up to Week 12","title":"Part A: Number of Participants With Incidence of Laboratory Test Abnormalities","type":"SECONDARY","unitOfMeasure":"Participants"}